down arrow

Cocrystal Pharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US19188J4094
USD
1.03
0.02 (2.48%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.011.04

52 Week

0.903.26
Valuation
Technical
Day's Volume

CASH

48.69 k

Shareholding (Mar 2025)

FII

0.03%

Held by 4 FIIs

DII

96.4%

Held by 4 DIIs

Promoter

0.00%

How big is Cocrystal Pharma, Inc.?

22-Jun-2025

As of Jun 18, Cocrystal Pharma, Inc. has a market capitalization of 16.18 million and reported net sales of 0.00 million with a net profit of -15.85 million over the last four quarters. Shareholder's funds are 9.52 million, and total assets amount to 13.46 million.

As of Jun 18, Cocrystal Pharma, Inc. has a market capitalization of 16.18 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -15.85 million during the same period.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 9.52 million and total assets amounting to 13.46 million.

Read More

What does Cocrystal Pharma, Inc. do?

22-Jun-2025

Cocrystal Pharma, Inc. is a clinical stage biotechnology company focused on developing antiviral therapeutics for serious viral diseases, with a market cap of $16.18 million and recent quarterly net profit of -$2 million.

Overview: <BR>Cocrystal Pharma, Inc. is a clinical stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious and chronic viral diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 16.18 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.92 <BR>Return on Equity: -216.99% <BR>Price to Book: 2.21<BR><BR>Contact Details: <BR>Address: 19805 N Creek Pkwy, BOTHELL WA: 98011-8251 <BR>Tel: ['1 786 4591831', '1 833 4758247'] <BR>Fax: 1 302 6365454 <BR>Website: https://www.cocrystalpharma.com/

Read More

Who are in the management team of Cocrystal Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of Cocrystal Pharma, Inc. includes Dr. Gary Wilcox as Chairman and CEO, with Dr. Roger Kornberg, Dr. Phillip Frost, Dr. Anthony Japour, and Mr. Steven Rubin serving as directors.

As of March 2022, the management team of Cocrystal Pharma, Inc. includes Dr. Gary Wilcox, who serves as the Chairman of the Board and Chief Executive Officer. Other members of the board include Dr. Roger Kornberg as a Director, Dr. Phillip Frost as an Independent Director, Dr. Anthony Japour as an Independent Director, and Mr. Steven Rubin as an Independent Director.

Read More

Is Cocrystal Pharma, Inc. overvalued or undervalued?

25-Jun-2025

As of August 16, 2021, Cocrystal Pharma, Inc. is considered overvalued with a valuation grade of "does not qualify" due to negative financial performance and ratios, including a Price to Book Value of 2.27 and a year-to-date return of -22.28%, significantly underperforming compared to its peers and the S&P 500.

As of 16 August 2021, Cocrystal Pharma, Inc. has moved from a valuation grade of risky to does not qualify. The company is currently considered overvalued given its negative financial performance and ratios. Key ratios include a Price to Book Value of 2.27, an EV to EBIT of -0.62, and a ROCE of -1606.10%. <BR><BR>In comparison to its peers, Cocrystal Pharma's valuation metrics are significantly worse; for instance, Entera Bio Ltd. has a PE ratio of -9.4138 and an EV to EBITDA of -7.4257, indicating a more favorable position despite also being classified as does not qualify. Additionally, Context Therapeutics, Inc. shows a PE of -1.8736 and an EV to EBITDA of 1.1859. The company's stock has underperformed relative to the S&P 500, with a year-to-date return of -22.28% compared to the S&P 500's 2.44%, reinforcing the notion of overvaluation.

Read More

Is Cocrystal Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Cocrystal Pharma, Inc. is in a mildly bearish trend, indicated by bearish MACD and Bollinger Bands, and has underperformed the S&P 500 with a year-to-date return of -37.13% compared to the S&P 500's 12.22%.

As of 8 September 2025, the technical trend for Cocrystal Pharma, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe, bearish Bollinger Bands across both weekly and monthly periods, and a bearish daily moving average. The KST indicates a mildly bearish trend on the weekly level, while the monthly shows a bearish stance. The Dow Theory reflects a mildly bearish trend on the weekly timeframe with no trend on the monthly. <BR><BR>In terms of performance, the stock has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -37.13% compared to the S&P 500's 12.22%, and a 1-year return of -27.43% against the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 15 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.85

stock-summary
Return on Equity

-235.53%

stock-summary
Price to Book

2.89

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-29.13%
0%
-29.13%
6 Months
-38.39%
0%
-38.39%
1 Year
-48.25%
0%
-48.25%
2 Years
-44.35%
0%
-44.35%
3 Years
-62.23%
0%
-62.23%
4 Years
-87.94%
0%
-87.94%
5 Years
-94.74%
0%
-94.74%

Cocrystal Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Cocrystal Pharma, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Cocrystal Pharma, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe, bearish Bollinger Bands across both weekly and monthly periods, and a bearish daily moving average. The KST indicates a mildly bearish trend on the weekly level, while the monthly shows a bearish stance. The Dow Theory reflects a mildly bearish trend on the weekly timeframe with no trend on the monthly. In terms of performance, the stock has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -37.13% compared to the S&P 500's 12.22%, and a 1-year return of -27.43% against the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-9.93%
EBIT to Interest (avg)
-11.78
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.92
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
7.69%
ROCE (avg)
0
ROE (avg)
0.95%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.27
EV to EBIT
-0.62
EV to EBITDA
-0.62
EV to Capital Employed
9.90
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1606.10%
ROE (Latest)
-216.99%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (3.58%)

Foreign Institutions

Held by 4 Foreign Institutions (0.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 60.38% vs -26.19% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.10",
          "val2": "-5.40",
          "chgp": "61.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.10",
          "val2": "-5.30",
          "chgp": "60.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 2.78% vs 53.61% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.80",
          "val2": "-22.50",
          "chgp": "20.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "2.60",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.50",
          "val2": "-18.00",
          "chgp": "2.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.10
-5.40
61.11%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.10
-5.30
60.38%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 60.38% vs -26.19% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-17.80
-22.50
20.89%
Interest
0.00
0.00
Exceptional Items
0.00
2.60
-100.00%
Consolidate Net Profit
-17.50
-18.00
2.78%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 2.78% vs 53.61% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Cocrystal Pharma, Inc. stock-summary
stock-summary
Cocrystal Pharma, Inc.
Pharmaceuticals & Biotechnology
Cocrystal Pharma, Inc., is a clinical stage biotechnology company. The Company focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C, influenza and norovirus. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The Company is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.
Company Coordinates stock-summary
Company Details
19805 N Creek Pkwy , BOTHELL WA : 98011-8251
stock-summary
Tel: 1 786 45918311 833 4758247
stock-summary
https://www.cocrystalpharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."